Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: Implications for cancer immunotherapy

Journal of Immunology

Volumn 191, Issue 7, 2013, Pages 3955-3967

  Pedersen, Sara R ^a   Sørensen, Maria R ^a   Buus, Søren ^a   Christensen, Jan P ^a   Thomsen, Allan R ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DOPACHROME TAUTOMERASE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DEGRANULATION; DNA SYNTHESIS; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN CELL;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEGRANULATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; FEMALE; GENETIC VECTORS; GP100 MELANOMA ANTIGEN; IMMUNOTHERAPY; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; MELANOCYTES; MICE; NEOPLASMS; PHENOTYPE; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC;

EID: 84885102010     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300555     Document Type: Article

References (60)

1. Dunn, G. P., A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998.
2. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570.
3. Blohm, U., D. Potthoff, A. J. van der Kogel, and H. Pircher. 2006. Solid tumors "melt" from the inside after successful CD8 T cell attack. Eur. J. Immunol. 36:468-477.
4. Boissonnas, A., L. Fetler, I. S. Zeelenberg, S. Hugues, and S. Amigorena. 2007. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J. Exp. Med. 204:345-356.
5. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:323-370.
6. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102:18538-18543.
7. Steer, H. J., R. A. Lake, A. K. Nowak, and B. W. Robinson. 2010. Harnessing the immune response to treat cancer. Oncogene 29:6301-6313.
8. Yamada, N., S. Oizumi, E. Kikuchi, N. Shinagawa, J. Konishi-Sakakibara, A. Ishimine, K. Aoe, K. Gemba, T. Kishimoto, T. Torigoe, and M. Nishimura. 2010. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol. Immunother. 59:1543-1549.
9. Kantoff, P. W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363:411-422.
10. Barefoot, B., N. J. Thornburg, D. H. Barouch, J. S. Yu, C. Sample, R. E. Johnston, H. X. Liao, T. B. Kepler, B. F. Haynes, and E. Ramsburg. 2008. Comparison of multiple vaccine vectors in a single heterologous prime-boost trial. Vaccine 26:6108-6118.
11. Bett, A. J., S. A. Dubey, D. V. Mehrotra, L. Guan, R. Long, K. Anderson, K. Collins, C. Gaunt, R. Fernandez, S. Cole, et al. 2010. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans. Vaccine 28:7881-7889.
12. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimiro, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigona, S. A. Dubey, et al. 2002. Replicationincompetent adenoviral vaccine vector elicits effective anti-immunodeficiencyvirus immunity. Nature 415:331-335.
13. Tatsis, N., and H. C. Ertl. 2004. Adenoviruses as vaccine vectors. Mol. Ther. 10:616-629.
14. Chailertvanitkul, V. A., and C. W. Pouton. 2010. Adenovirus: a blueprint for nonviral gene delivery. Curr. Opin. Biotechnol. 21:627-632.
15. Holst, P. J., M. R. Sorensen, C. M. Mandrup Jensen, C. Orskov, A. R. Thomsen, and J. P. Christensen. 2008. MHC class II-associated invariant chain linkage of antigen dramatically improves cell-mediated immunity induced by adenovirus vaccines. J. Immunol. 180:3339-3346.
16. + T-cell-mediated tumor control. Eur. J. Immunol. 39:2725-2736.
17. Bakker, A. B., M. W. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005-1009.
18. Parkhurst, M. R., E. B. Fitzgerald, S. Southwood, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1998. Identification of a shared HLA-A 0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 58:4895-4901.
19. Theos, A. C., S. T. Truschel, G. Raposo, and M. S. Marks. 2005. The Silver locus product Pmel17/gp100/Silv/ME20:controversial in name and in function. Pigment Cell Res. 18:322-336.
20. Mendiratta, S. K., G. Thai, N. K. Eslahi, N. M. Thull, M. Matar, V. Bronte, and F. Pericle. 2001. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2. Cancer Res. 61:859-863.
21. Perricone, M. A., K. A. Claussen, K. A. Smith, J. M. Kaplan, S. Piraino, S. Shankara, and B. L. Roberts. 2000. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol. Ther. 1:275-284.
22. Fong, L., C. L. Ruegg, D. Brockstedt, E. G. Engleman, and R. Laus. 1997. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159:3113-3117.
23. Mamula, M. J., R. H. Lin, C. A. Janeway, Jr., and J. A. Hardin. 1992. Breaking T cell tolerance with foreign and self co-immunogens: a study of autoimmune B and T cell epitopes of cytochrome c. J. Immunol. 149:789-795.
24. Gold, J. S., C. R. Ferrone, J. A. Guevara-Patiño, W. G. Hawkins, R. Dyall, M. E. Engelhorn, J. D. Wolchok, J. J. Lewis, and A. N. Houghton. 2003. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 170:5188-5194.
25. Overwijk, W. W., A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, and N. P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
26. + T cells. J. Exp. Med. 198:569-580.
27. Schreurs, M. W., A. J. de Boer, C. G. Figdor, and G. J. Adema. 1998. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. 58:2509-2514.
28. Diebold, S. S., M. Cotten, N. Koch, and M. Zenke. 2001. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8:487-493.
29. Becker, T. C., R. J. Noel, W. S. Coats, A. M. Gomez-Foix, T. Alam, R. D. Gerard, and C. B. Newgard. 1994. Use of recombinant adenovirus for metabolic engineering of mammalian cells. Methods Cell Biol. 43(Pt. A):161-189.
30. Fidler, I. J. 1975. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res. 35:218-224.
31. Prévost-Blondel, A., C. Zimmermann, C. Stemmer, P. Kulmburg, F. M. Rosenthal, and H. Pircher. 1998. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. J. Immunol. 161:2187-2194.
32. Janik, P., P. Briand, and N. R. Hartmann. 1975. The effect of estroneprogesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 35:3698-3704.
33. + T cell functionality in virus-infected mice lacking a normal B cell compartment. J. Immunol. 171:4733-4741.
34. Cobbold, S. P., A. Jayasuriya, A. Nash, T. D. Prospero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312:548-551.
35. Pedersen, A. E., S. Buus, and M. H. Claesson. 2006. Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett. 235:229-238.
36. Qin, S., S. Cobbold, H. Tighe, R. Benjamin, and H. Waldmann. 1987. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction. Eur. J. Immunol. 17:1159-1165.
37. Barber, D. L., E. J. Wherry, and R. Ahmed. 2003. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171:27-31.
38. + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods 281:65-78.
39. Fukuda, M. 1991. Lysosomal membrane glycoproteins; structure, biosynthesis, and trafficking to lysosome. J. Biol. Chem. 266:21327-21330.
40. + T cell fates via the graded expression of T-bet transcription factor. Immunity 27:281-295.
41. Denoeud, J., and M. Moser. 2011. Role of CD27/CD70 pathway of activation in immunity and tolerance. J. Leukoc. Biol. 89:195-203.
42. + T cell dysfunction in melanoma patients. J. Exp. Med. 207:2175-2186.
43. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 107:7875-7880.
44. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207:2187-2194.
45. Zhou, Q., M. E. Munger, R. G. Veenstra, B. J. Weigel, M. Hirashima, D. H. Munn, W. J. Murphy, M. Azuma, A. C. Anderson, V. K. Kuchroo, and B. R. Blazar. 2011. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117:4501-4510.
46. Dudley, M. E., M. I. Nishimura, A. K. Holt, and S. A. Rosenberg. 1999. Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J. Immunother. 22:288-298.
47. McMahan, R. H., and J. E. Slansky. 2007. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin. Cancer Biol. 17:317-329.
48. Yang, S., G. P. Linette, S. Longerich, and F. G. Haluska. 2002. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity. J. Immunol. 169:531-539.
49. Zeh, H. J., III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989-994.
50. Chen, M. L., M. J. Pittet, L. Gorelik, R. A. Flavell, R. Weissleder, H. von Boehmer, and K. Khazaie. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo. Proc. Natl. Acad. Sci. USA 102:419-424.
51. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-685.
52. Thomas, D. A., and J. Massagué. 2005. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380.
53. Wing, K., and S. Sakaguchi. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11:7-13.
54. Vesely, M. D., M. H. Kershaw, R. D. Schreiber, and M. J. Smyth. 2011. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29:235-271.
55. Turk, M. J., J. A. Guevara-Patiño, G. A. Rizzuto, M. E. Engelhorn, S. Sakaguchi, and A. N. Houghton. 2004. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J. Exp. Med. 200:771-782.
56. Kündig, T. M., M. F. Bachmann, L. Lefrancois, L. Puddington, H. Hengartner, and R. M. Zinkernagel. 1993. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J. Immunol. 150:4450-4456.
57. Sørensen, M. R., and A. R. Thomsen. 2007. Virus-based immunotherapy of cancer: what do we know and where are we going? APMIS 115:1177-1193.
58. Speiser, D. E., D. Liénard, M. J. Pittet, P. Batard, D. Rimoldi, P. Guillaume, J. C. Cerottini, and P. Romero. 2002. In vivo activation of melanoma-specific CD8+ T cells by endogenous tumor antigen and peptide vaccines: a comparison to virus-specific T cells. Eur. J. Immunol. 32:731-741.
59. Sorensen, M. R., P. J. Holst, M. A. Steffensen, J. P. Christensen, and A. R. Thomsen. 2010. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine 28:6757-6764.
60. Landsberg, J., J. Kohlmeyer, M. Renn, T. Bald, M. Rogava, M. Cron, M. Fatho, V. Lennerz, T. Wölfel, M. Hölzel, and T. Tüting. 2012. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490:412-416